COL23A1 rs2973744 and Eczema Herpeticum Susceptibility

Medical safety first: suspected eczema herpeticum is urgent. Rapidly spreading painful blisters or punched-out sores, fever, unusual sleepiness, dehydration, worsening pain, or any rash near the eye should be assessed the same day. Eye pain, light sensitivity, vision change, severe illness, or a very young or immunocompromised patient can require emergency care. Do not wait for an online article to confirm the diagnosis.

COL23A1 rs2973744 and Eczema Herpeticum Susceptibility examines one specific part of a complex infection question. The primary paper is indexed in PubMed as PMID 40562081. [1] This research summary separates what the study observed from what families and clinicians can safely do now.

What the study asked

The investigators used a genetic and keratinocyte follow-up study to study a COL23A1 variant, functional follow-up, and the need for population replication. That design matters. A cohort or registry can describe patterns and associations; a sequencing or laboratory study can identify biological leads; a case series can show clinical variety. None of these designs alone proves that a measured factor caused infection or that changing it would prevent infection.

Lipid measurements add a barrier-biology perspective, although circulating and skin lipids can be influenced by treatment, diet, age and inflammation. Related eczema-herpeticum studies show that susceptibility is heterogeneous: disease activity, barrier disruption, viral exposure, immune response, treatment, age and access to timely care may all influence the observed picture. [2] [3] [4]

What can reasonably be concluded

• The focal paper used a genetic and keratinocyte follow-up study to examine a COL23A1 variant, functional follow-up, and the need for population replication. [1]
• Its results should be read as evidence about the studied group and design—not proof that the measured feature caused eczema herpeticum. [2] [3]
• Recognition and prompt clinician assessment remain more actionable than experimental biomarker or genetic testing. [4] [18]
• Infants, children, immunocompromised people, and anyone with eye-area symptoms deserve a particularly low threshold for urgent evaluation. [19] [20]

The paper adds evidence about a COL23A1 variant, functional follow-up, and the need for population replication. It does not create a home screening test, prove a single causal pathway, or justify changing a prescription without the treating clinician. Results from a selected specialty cohort may not apply to people with milder eczema, different ancestry, different healthcare access, or different treatment exposure.

What eczema herpeticum is—and is not

Eczema herpeticum is a potentially serious, disseminated herpes simplex infection that can occur on skin affected by atopic dermatitis. Painful or rapidly spreading clusters of similar-looking blisters or punched-out erosions, fever, marked fatigue, or eye-area involvement require urgent same-day medical assessment. A clinician may begin antiviral treatment when the diagnosis is strongly suspected rather than waiting for every test result, because timing can matter. Bacterial infection can coexist with viral infection, but an antibiotic does not treat herpes simplex virus and an antiviral does not replace bacterial evaluation when that is needed. Neither eczema severity nor a history of cold sores can determine by itself who will develop eczema herpeticum. [18] [19]

Eczema herpeticum can be confused with impetigo, an ordinary eczema flare, contact dermatitis, hand-foot-and-mouth disease, varicella, or other blistering conditions. Photographs and symptom descriptions are not reliable substitutes for examination. Clinicians may use viral PCR or another test, but sampling timing, lesion selection and prior treatment can affect results. A negative result does not automatically resolve a high-risk clinical picture.

Why association is not causation

People with more severe or persistent eczema are more likely to receive systemic treatment, see specialists, have cultures or viral testing, and enter registries. They may also have more opportunities for infection to be documented. This creates confounding by disease severity and healthcare contact. In molecular studies, inflammation or treatment can change the very biomarker being measured, creating reverse-causation concerns. [5] [6] [7]

Small samples can produce unstable estimates, especially for genetic variants, immune-cell subgroups or rare recurrent events. Multiple-comparison testing can also identify chance signals. Replication in independent populations, transparent analysis plans and clinically meaningful validation are needed before a signal becomes a useful test. [8] [9] [10]

Infants and children: practical safety boundaries

Babies and young children can become dehydrated or systemically unwell quickly. Caregivers should seek prompt medical advice for fever, reduced drinking, fewer wet diapers, unusual drowsiness, rapidly worsening pain, extensive blistering, or lesions near the eyes. Do not apply topical anesthetics, essential oils, bleach, household antiseptics or another person's prescription medicine to suspected viral lesions. Do not intentionally expose a child to a cold sore to “build immunity.” [11] [12] [20]

A parent or caregiver with an active cold sore should avoid kissing a baby or touching the baby's eczema after touching the sore, wash hands carefully, and follow clinician advice about lesion coverage and contact. These steps reduce exposure opportunity but cannot guarantee prevention.

Treatment evidence needs clinical supervision

Prescription antivirals are the core medical therapy when eczema herpeticum is suspected or confirmed. The medicine, dose, route and duration depend on age, weight, kidney function, severity, ability to drink, eye involvement and overall condition. Children must never be given leftover adult medication. Antibiotics may be added when bacterial infection is also suspected; they are not substitutes for antiviral treatment. [13] [14] [15]

People taking biologics, oral JAK inhibitors, conventional immunosuppressants or other immune-modifying medicines should contact the prescribing clinician for individualized instructions. Do not abruptly stop or restart a prescription solely because of this article. Pregnancy, breastfeeding, immune compromise and kidney disease require clinician-specific decisions.

What remains uncertain

The study cannot settle every question about prediction, recurrence or prevention. Residual confounding, referral bias, coding accuracy, sample collection, treatment exposure, ancestry, geographic setting and changing diagnostic practices can all shape results. Rare-event estimates often have wide uncertainty even when a database is large. Laboratory mechanisms may be biologically plausible without being clinically actionable. [16] [17] [21]

A useful next step for research would combine prospectively collected symptoms, clinician-confirmed viral testing, standardized eczema severity, medication exposure and repeated barrier or immune measurements. That design could clarify timing and improve prediction while reducing reverse-causation problems.

Where moisturizer fits—and where it does not

Routine fragrance-free moisturizing can support comfort and barrier care in eczema-prone skin, but a cosmetic moisturizer is not an antiviral, antibiotic or treatment for eczema herpeticum. The intervention, assay or treatment studied in PMID 40562081 was not Dr. Arsy Moisturizer #003, 4 oz. Study-specific efficacy, prevention or infection results must not be transferred to #003. Avoid applying routine cosmetic products directly to painful open or weeping lesions unless the treating clinician advises it.

Related Dr. Arsy research reading

• Infection and eczema safety guide
• Infection and eczema safety guide
• Infection and eczema safety guide
• Infection and eczema safety guide
• Dupilumab Infection Risk in a 10,913-Patient Matched Global Cohort
• Changing Incidence of Kaposi Varicelliform Eruption in Atopic Dermatitis
• Herpes Superinfection Across 34 Active-Dermatosis Cases
• Kaposi Varicelliform Eruption: Clinical Spectrum in a Case Series

Bottom line

This genetic and keratinocyte follow-up study contributes evidence about a COL23A1 variant, functional follow-up, and the need for population replication, but it does not turn a complex emergency infection into a simple risk score. The safest practical message is recognition: painful, rapidly spreading, similar-looking blisters or erosions—especially with fever or eye-area involvement—need urgent clinical assessment. Mechanistic and observational findings should guide better research, not self-diagnosis or unsupervised treatment.

References

1. COL23A1 rs2973744 and Eczema Herpeticum Susceptibility. PubMed PMID 40562081.
2. Dupilumab Infection Risk in a 10,913-Patient Matched Global Cohort. PubMed PMID 40415482.
3. Changing Incidence of Kaposi Varicelliform Eruption in Atopic Dermatitis. PubMed PMID 18583798.
4. Herpes Superinfection Across 34 Active-Dermatosis Cases. PubMed PMID 28242091.
5. Kaposi Varicelliform Eruption: Clinical Spectrum in a Case Series. PubMed PMID 26753139.
6. Kaposi Varicelliform Eruption in a 14-Case Indian Series. PubMed PMID 40918711.
7. Eczema Herpeticum: Barrier, Immunity and Microbiome Evidence Review. PubMed PMID 31836943.
8. Recurrent Eczema Herpeticum in 224 European Cases. PubMed PMID 31733162.
9. Eczema Herpeticum Recurrence in the 893-Patient TREATgermany Registry. PubMed PMID 37814394.
10. Pediatric Eczema Herpeticum: Hospitalization Predictors in 79 Children. PubMed PMID 22575249.
11. Delayed Acyclovir in 1,331 Hospitalized Children With Eczema Herpeticum. PubMed PMID 22084327.
12. Whole-Genome Sequencing in 49 Recurrent Eczema Herpeticum Cases. PubMed PMID 33548076.
13. Sphingolipid Biomarkers in Eczema Herpeticum-Prone Atopic Dermatitis. PubMed PMID 35304160.
14. Eczema Herpeticum in 4,655 Weighted US Pediatric Hospitalizations. PubMed PMID 28927889.
15. Eczema Herpeticum Among 180 Pediatric Skin-Infection Encounters. PubMed PMID 31764378.
16. The Clinical Phenotype Associated With Eczema Herpeticum History. PubMed PMID 19541356.
17. Interferon-Gamma Responses and Eczema Herpeticum Susceptibility. PubMed PMID 21458658.
18. American Academy of Dermatology atopic dermatitis clinical guidelines.
19. NICE guideline CG57: atopic eczema in under 12s.
20. American Academy of Pediatrics: Atopic Dermatitis—Update on Skin-Directed Management.
21. CDC: About genital herpes and herpes simplex virus.

This article is educational and is not a diagnosis or individualized medical advice. Its featured image is an AI-created research illustration; it does not show a study participant or a verified clinical appearance. Dr. Arsy #003 was not the study product.